Marker Lesion Experiments in Bladder Cancer-What Have We Learned?

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 1678-1685

  Gofrit, Ofer N ^a   Zorn, Kevin C ^b   Shikanov, Sergey ^b   Steinberg, Gary D ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

antineoplastic agents; ethics; patient selection; research; safety; urinary bladder neoplasms

Indexed keywords

ALPHA INTERFERON; APAZIQUONE; BCG VACCINE; EPIRUBICIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MITOMYCIN C; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA; VALRUBICIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; MEDICAL ETHICS; MEDLINE; MICTURITION DISORDER; NAUSEA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CATHETER ABLATION; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 77950519080     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.12.104     Document Type: Review

References (30)

1. Koontz Jr. W.W., Prout Jr. G.R., Smith W., et al. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol 125 (1981) 307
2. Heney N.M., Koontz W.W., Barton B., et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 140 (1988) 1390
3. Calais daSilva F., Denis L., Bono A., et al. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 14 (1988) 207
4. Cumming J.A., Kirk D., Newling D.W., et al. A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. Eur Urol 17 (1990) 20
5. Serretta V., Corselli G., Piazza B., et al. Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. Eur Urol 22 (1992) 112
6. Fellows G.J., Parmar M.K., Grigor K.M., et al. Marker tumour response to Evans and Pasteur bacille Calmette-Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol 73 (1994) 639
7. Popert R.J., Goodall J., Coptcoat M.J., et al. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol 74 (1994) 195
8. Van derMeijden A.P., Hall R.R., Macaluso M.P., et al. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29 (1996) 199
9. Bono A.V., Hall R.R., Denis L., et al. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol 29 (1996) 385
10. Brausi M., Campo B., Pizzocaro G., et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 51 (1998) 506
11. Den Otter W., Dobrowolski Z., Bugajski A., et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159 (1998) 1183
12. Stravoravdi P., Toliou T., Kirtsis P., et al. A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa. J Interferon Cytokine Res 19 (1999) 221
13. Mack D., Höltl W., Bassi P., et al. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401
14. Newling D.W., Hetherington J., Sundaram S.K., et al. The use of valrubicin for the chemoresection of superficial bladder cancer-a marker lesion study. Eur Urol 39 (2001) 643
15. Malmström P.U. A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89 (2002) 681
16. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339
17. Gårdmark T., Carringer M., Beckman E., et al. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder. Urology 66 (2005) 527
18. Serretta V., Galuffo A., Pavone C., et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology 65 (2005) 65
19. van derHeijden A.G., Moonen P.M., Cornel E.B., et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176 (2006) 1349
20. Puri R., Palit V., Loadman P.M., et al. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. J Urol 176 (2006) 1344
21. Maffezzini M., Campodonico F., Canepa G., et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 51 (2007) 956
22. Sidi A.A., Ohana P., Benjamin S., et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 180 (2008) 2379
23. Hendricksen K., van derHeijden A.G., Cornel E.B., et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 27 (2009) 337
24. van derMeijden A.P., Hall R.R., Kurth K.H., et al. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Br J Urol 77 (1996) 634
25. Gofrit O.N., Pode D., Lazar A., et al. Watchful waiting policy in recurrent Ta G1 bladder tumor. Eur Urol 49 (2006) 303
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1
27. Oosterlinck W., Bono A.V., Mack D., et al. Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol 40 (2001) 515
28. van derMeijden A.P. The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified?. Urol Oncol 7 (2002) 31
29. Jain A., Phillips R.M., Scally A.J., et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73 (2009) 1083
30. Sylvester R.J., van derMeijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466